Human telomerase RNA ( hTR ), an important component of telomerase, is a possible target of telomerase -based cancer gene therapy. The present study was undertaken to assess the efficacy of antisense hTR therapy using newly developed 2 -5A ( 5 0 -phosphorylated 2 0 -5 0 -linked oligoadenylate ) -linked oligonucleotides against cervical cancer cells. ME180 and SiHa cells were treated with 2 -5A -linked antisense hTR designed to complement the region of hTR between residues 76 and 94. The hTR expression, telomerase activity, cell viability, and apoptosis were then examined. The 2 -5A anti -hTR effectively degraded hTR and inhibited telomerase activity. The 2 -5A mutant anti -hTR and the anti -hTR without 2 -5A were not capable of inhibiting telomerase activity. Inhibition of telomerase by 2 -5A anti -hTR rapidly decreased cell viability only in telomerase -positive cells within 3 -6 days after the treatment, when telomere length has not yet been shortened. This inhibition was associated with apoptosis, possibly through activation of caspase family members. These findings suggest that 2 -5A -linked antisense -hTR therapy has a potent telomeraseinhibitory effect associated with a cytocidal effect from caspase -induced apoptosis, and may therefore be a potential tool in telomerase -based gene therapy against cervical cancers.
T elomeres are specialized structures composed of TT AGGG repeats at the ends of eukaryotic chromosomes. 1 This structure protects chromosomes against degradation, end -to -end fusions, rearrangements, and chromosome loss, thus contributing to chromosomal stabilization. Due to the inability of DNA polymerase to completely replicate the end of chromosomes, telomeres shorten with each cell division. 2 Telomerase is a ribonucleoprotein complex that elongates telomere sequences at the termini of chromosome DNA. 3 Because this enzyme is repressed in normal somatic cells, telomeres progressively shorten over a substantial number of cell divisions; telomeres under the threshold length are hypothesized to induce cellular senescence, possibly due to the induction of DNA damage responses, including p53 or p21 activation. 4, 5 Telomerase activation is therefore required for cells to prevent progressive telomere loss and overcome replicative senescence. 6 Recent studies have revealed that telomerase activity is detected in the majority of malignant tumors but not in normal somatic cells, suggesting that telomerase activation is the major step for carcinogenesis. 7 These observations suggest a therapeutic opportunity for overcoming cancer cells by inhibiting the telomerase activity.
Telomerase is composed of three major subunits: the template RNA component ( hTR ), 8 the telomeraseassociated protein (TP1 ), 9, 10 and the telomerase reverse transcriptase (hTERT ). 11, 12 The hTERT is a catalytic subunit protein that contains reverse transcriptase motif ( RT ) conserved over species and bears the enzymatic activity of telomerase. The RNA component hTR contains template sequences (AAUCCCAAU ) through which telomerase can extend telomeric repeats. The role of TP1 remains unclear, but a recent study indicated that this factor does not play a significant role in the maintenance of telomere length. 13 These findings suggest that both hTERT and hTR may be potential targets of telomerase-based cancer gene therapy. Antisense -based strategies against hTR have been attempted in various cancer cells. Feng and colleagues first successfully inhibited telomerase activity by introducing antisense -hTR expression vectors into HeLa cells. 8 Subsequent studies have also reported inhibition of hTR by exogenous administration of antisense DNA against hTR. 14 -16 However, the effects of antisense hTR appear to be limited, possibly due to insufficient inhibition of hTR. Modified antisense strategies have been applied against hTR using peptide nucleic acids or 2 0 -o -methyl RNA, and improved results have been reported. 17, 18 Recently, the superior effect of an antisense oligonucleotide linked to 2 -5A ( 5 0 -phosphorylated 2 0 -5 0 -linked oligoadenylate ) has been demonstrated. 19 The 2-5A molecule is a mediator of one pathway of interferon action. The 2 -5A molecule activates RNase L that is ubiquitous in mammalian cells, resulting in single -strand RNA cleavage. Antisense against a certain target linked to 2-5A is thought to effectively degrade the targeted RNA in a highly specific manner and enhance the potency of antisense DNA by at least 20-fold. In this study, we sought to apply this novel technology to gene therapy against cervical cancers. We aimed to successfully degrade hTR by introducing 2 -5A -linked anti -hTR into telomerase -positive cervical cancer cells, thus leading to the complete blockade of telomerase activity.
Materials and methods

Cell cultures
Human uterine cervical cancer cell lines ME180, SiHa, and C33A were purchased from American Type Culture Collection ( Manassas, VA ) and were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum in the presence of 5% CO 2 at 378C. Telomerase -negative cell lines SUSM and WI -38VA13 / 2RA cells were obtained from RIKEN (Tsukuba, Japan ) and Health Science Research Resources Bank ( Osaka, Japan ), respectively. Human renal corticoepithelial cells ( HRCE ) were purchased from Clonetics ( San Diego, CA ) and were cultured according to the provider's protocol. Normal human cervical epithelial cells were isolated from cervical samples taken from a patient undergoing surgery for a uterine myoma.
Telomerase assay
To measure the telomerase activity, the telomeric repeat amplification protocol ( TRAP ) assay was performed as described previously. 20 The amplification products were electrophoresed in a 12% polyacrylamide gel and stained using SYBR Green I 2 stain ( FMC BioProducts, Rockland, ME ).
RT -PCR analysis
Analysis of the expression of hTR was performed by reverse transcription -polymerase chain reaction ( RT-PCR ) amplification as previously described 21 using the primer pair 5 0 -TCTAACCCTAACTGAGAAGGGCGTAG -3 0 ( F3b) and 5 0 -GTTTGCTCTAGAATGAACGGTGGAAG-3 0 (R3c). Total RNA was isolated from the tissues using Isogen 2 commercial product ( Nippon Gene, Otsu, Japan ) according to the manufacturer's protocol. Complementary DNA was synthesized from 1 g of RNA using a commercial RNA PCR kit Version 2 ( TaKaRa ) with random primers. To amplify the cDNA, 2 -l aliquots of the reverse-transcribed cDNA were subjected to 28 cycles of PCR amplification in Amplification products were electrophoresed in a 7% polyacrylamide gel and stained with SYBR Green I 2 stain ( FMC BioProducts ). The efficiency of cDNA synthesis from each sample was estimated by PCR with GAPDH -specific primers as previously described. 21 
Oligonucleotides
The selection of the antisense sequence against hTR was described previously. 22 Briefly, 2 -5A molecules were linked to antisense oligonucleotides that were designed to complement the region between residues 76 and 94, predicted to be the most open region from the MFOLD program. The sequence of the antisense oligonucleotide is 5 0 -GCG CGG GGA GCA AAA GCA C -3
0
. For investigating the effects of 2 -5A -linked antisense hTR, control oligonucleotides were also synthesized. Mutant 2 -5A -linked antisense -hTR oligonucleotide (MT 2 -5A anti -hTR ) contains six mismatched nucleotides in antisense sequences that would prevent homologous binding with the telomerase RNA. Wild -type ( WT ) or mutant (MT ) antisense hTRs without 2 -5A were also synthesized. These chimeric oligonucleotides were synthesized at Hybridon ( Milford, MA ).
Cell viability assay
Cell viability after administration of oligonucleotides was determined using the WST-1 assay according to the manufacturer's protocol (Boehringer Mannheim, Indianapolis, IN ). The cells were seeded at 5Â10 3 cells /well in 96 -well flat -bottomed plates and incubated overnight at 378C. 
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The oligonucleotides were then added to the media every 24 hours in the following way. The culture medium was removed and 10 l of 5 M oligonucleotides mixed with 0.3 l LipofectAMINE 2 reagent (Invitrogen, Carlsbad, CA ) was added to each well, then the plates were incubated for 1 minute at room temperature. A 90 -l aliquot of medium was then added to each well to bring the final concentration of oligonucleotides to 0.5 M. The cell viability of the treated cells was expressed as relative WST-1 activity. The WST-1 activity in cells just before the treatment on day 1 was normalized to 100%.
Colony -formation assay
Five hundred single ME180 cells were prepared by sufficient trypsinization and repeated pipetting, seeded on 24-well dishes, incubated for 24 hours, and treated with WT or MT 2 -5A anti-hTR or lipofectamine alone for 48 hours at 378C. The colony number was counted after Giemsa staining.
Telomere length analysis by Southern blotting
High -molecular-weight DNA was extracted from cultured cells on 6 -cm dishes using a commercial kit (QIAamp 2 DNA Mini Kit; QIAGEN, Valencia, CA ). A 5 -g aliquot of DNA was digested with HinfI, subjected to electrophoresis on a 0.7% agarose gel, blotted onto nitrocellulose filters, and then hybridized to a [ 32 P ]ATP -labeled (TTAGGG ) 4 probe at 428C. The filters were washed once in 5Â SSC ( 1Â = 0.15 M NaCl, 0.015 M sodium citrate ) with 0.1% sodium dodecyl sulfate ( SDS ) for 15 minutes at RT and twice in 1Â SSC with 0.1% SDS for 15 minutes each at 428C, and then exposed for autoradiography. The mean terminal restriction fragment ( TRF ) lengths were visualized and measured by densitometry.
Flow -cytometric analysis of apoptosis
To provide a comparative assay of apoptosis by annexin V labeling, ME180 cells (1Â10 5 ) were treated with or without 2 -5A anti -hTR for 2 days and were harvested, washed, fixed with ice -cold 70% ethanol ( 50 minutes, 48C ), and resuspended in binding buffer (10 mM HEPES/ NaOH [pH 7.4 ], 140 mM NaCl, and 2.5 mM CaCl 2 ). The cells then received 15 l of FITC -annexin V (R&D System, Minneapolis, MN ) and were incubated for 15 minutes in the dark at room temperature before flowcytometric analysis.
Caspase inhibition assay
Functional involvement of caspases was examined by inhibition of the enzymes. Cells were seeded at 5Â10 3 /well in 96 -well flat -bottomed plates, incubated for 24 hours at 378C, and treated with WT 2-5A anti -hTR every 24 hours in the presence or absence of either ICE inhibitors or CPP32 inhibitor (Biomol Research Laboratories, Plymouth Meeting, PA ) at 50 M, and cell viability assays were performed on day 4 as described above.
Results
-5A -linked antisense hTR effectively inhibits hTR expression in telomerase -positive uterine cervical cancer cells
We first examined the telomerase activity in ME180, SiHa, and C33A cells derived from cervical cancers by the TRAP assay. As shown in Figure 1A , all the cell lines tested were telomerase positive. In contrast, telomerase activity was undetectable in primary -cultured cells from normal tissues, such as cervix, kidney (HRCE ), and foreskin (NHF ).
A 2-5A -linked antisense oligonucleotide against hTR ( WT 2 -5A anti -hTR ) was synthesized (Table 1) , in which the RNA region of hTR between residues 76 and 94 was targeted because this region is predicted to be exposed in a three -dimensional structure of hTR and is therefore thought to be a good target of antisense strategy. As control oligonucleotides, 2-5A -linked mutant oligonucleotides were synthesized in which targeted sequences were mutated with substitutions ( MT 2 -5A anti -hTR ) ( Table 1 ). We then 
Bu: butanediol linkers. Underline indicates mismatched nucleotides. Figure 2 2 -5A antisense hTR inhibits telomerase activity in ME180 cells in a sequence -specific manner. ME180 cells were treated with wild -type ( WT ) or mutant ( MT ) antisense hTR with or without 2 -5A. Cell lysates were recovered 4 days after the treatments and subjected to TRAP assays.
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Telomerase inhibition by 2-5A antisense hTR N Yatabe et al examined the effect of these oligonucleotides on hTR expression. The ME180 cells were treated with WT-or MT 2 -5A anti-hTR at 0.5 M for 48 h; then the RNAs were extracted and RT-PCR assay was performed to detect hTR expression. As shown in Figure 1B , the expression of hTR was apparently decreased by the treatment with WT 2 -5A anti -hTR, whereas no significant change in hTR expression was observed after treatment with MT 2 -5A anti-hTR. Thus, 2-5A anti -hTR inhibited hTR expression in a target sequence -specific manner. Similar results were obtained in SiHa cells ( data not shown ).
-5A -linked antisense hTR inhibits telomerase activity and cell viability in only telomerase -positive cells
We next assessed the effect of 2 -5A anti -hTR on telomerase activity in ME180 cells. The cells were treated with WT or MT anti -hTR with or without 2 -5A for 4 days before the TRAP assay was performed. A substantial decrease in telomerase activity was observed in cells treated with WT 2 -5A anti -hTR, whereas no significant change in activity was observed in cells treated with MT 2-5A antihTR or antisense hTR without 2 -5A (Fig 2 ) . These findings suggest that the inhibitory effect was not due to the nonspecific action of 2 -5A and that the antisense effect is not sufficient to inhibit telomerase activity in these cells. Similar results were obtained in SiHa cells ( data not shown ). We then investigated whether reduced telomerase activity affects cell viability. The ME180 or SiHa cells were treated with WT or MT anti -hTR combined or uncombined with 2 -5A for 5 days and the cell viability was examined by WST-1 assay. As shown in Figure 3 , treatment of ME180 cells with WT 2-5A anti-hTR significantly reduced cell viability in a time -dependent manner. The viability of ME180 cells treated with WT 2-5A anti -hTR for 3 days was 70% of the control, viability at 4 days was 68%, and viability at 5 days was 43%. In SiHa cells, the cell viability of treated cells for 3 days was 65% of the control, viability at 4 days was 49%, and viability at 5 days was 39%. In contrast, no significant change in cell viability was observed in cells treated with MT 2 -5A anti-hTR, WT, or MT anti -hTR without 2 -5A. Thus, WT 2 -5A anti -hTR exhibited a cytocidal effect on cervical cancer cells in a sequence -specific manner. We also examined the effects of these oligonucleotides on cell viability of telomerase-negative cells using normal human renal epithelial cells (HRCE ) or normal foreskin fibroblasts that lack telomerase activity as shown in Figure 1A . We also used 
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Telomerase inhibition by 2-5A antisense hTR N Yatabe et al SUSM -1 and WI -38VA13 /2RA cells, immortal cell lines that lack telomerase activity (confirmed by our TRAP assay; Fig 1A ) . 23 These cells were treated with oligonucleotide for 5 days before WST-1 assays were performed (Fig 3C ) . No significant change in cell viability was observed in cells treated with WT 2-5A anti -hTR or other oligonucleotides, suggesting that the effect of WT 2-5A anti -hTR is specific to telomerase -positive cells.
We further confirmed the effect of 2-5A anti -hTR on cell growth by colony formation assay. Five hundred single ME180 cells were seeded on the dishes and treated with WT or MT 2-5A anti -hTR or lipofectamine alone for 4 days before the colony number was counted. A significant reduction in colony -forming ability was observed in WT 2 -5A -treated cells ( Fig 4 ) compared to lipofectamine -or MT 2-5A -treated cells, further supporting the sequencespecific growth -inhibitory effect of 2-5A anti -hTR in cervical cancer cells.
Cytocidal effect of 2 -5A anti -hTR is not attributed to telomere shortening
To examine whether decreased cell viability is associated with telomere shortening, we evaluated the telomere lengths of ME 180 cells before and after the treatment with 2 -5A anti-hTR by measuring the length of the TRFs. As shown in Figure 5 , the mean TRF length of ME180 cells was determined to be approximately 3 kb, which slightly shortened during treatments for 5 days but did not differ in cells treated with lipofectamine alone or 2-5A anti -hTR. Thus, treatment with 2 -5A anti-hTR did not affect telomere length in such a short period. These findings, together with the findings of rapid kinetics of cell viability, suggest that loss of cell viability does not result from telomere impairment.
-5A -linked antisense hTR induces apoptosis in cervical cancer cells through activation of the caspase pathway
We next sought to analyze the mechanisms of the cytocidal effect of 2-5A anti -hTR. Flow cytometric analyses were performed to examine whether the cytocidal effect is due to the induction of apoptosis. The ME180 cells were treated with WT 2 -5A anti -hTR or lipofectamine alone for 48 hours, and annexin V -labeled cells were evaluated by flow cytometry. The WT 2-5A anti -hTR treatment resulted in a significant increase in annexin V -positive apoptotic cells up to 13.0% compared to 0.2% in control samples treated with lipofectamine alone, suggesting that the effect of 2 -5A anti-hTR was mainly achieved by the induction of apoptosis ( Fig 6) . To identify the pathway of apoptosis induced by this agent, a caspase inhibition assay was performed in which ME180 cells were treated with WT 2-5A anti -hTR for 6 days in the presence or absence of caspase inhibitors (ICE inhibitor or CPP32 inhibitor ). As shown in Figure 7 , WT 2 -5A anti -hTR treatment resulted in 57% decrease in cell viability in ME180 cells. Interestingly, addition of ICE inhibitor recovered cell viability up to 88% versus control samples treated with lipofectamine alone. The CPP32 inhibitor represented similar effects. The treatment of MT 2 -5A anti -hTR did not affect cell viability and recovery of cell viability by caspase inhibitors was not therefore obvious in this group (data not shown). These results indicate the Figure 5 Telomere length is not altered during the treatment with 2 -5A antisense hTR. ME180 cells were untreated or treated with lipofectamine alone or wild -type 2 -5A antisense hTR for 5 days. The DNAs were then extracted and subjected to Southern blot analysis of the TRF lengths. Figure 6 Induction of apoptosis by 2 -5A antisense hTR. ME180 cells were treated with lipofectamine or 2 -5A anti -hTR for 2 days and then subjected to flow cytometric analysis using FITC -labeled annexin as an apoptosis marker.
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Discussion
In the present study, we demonstrated the effect of 2 -5A -linked antisense oligonucleotide against hTR on telomerase activity and cell viability in cervical cancer cells. The 2 -5A antisense hTR effectively degraded hTR and inhibited telomerase activity associated with decreased cell viability. The inhibitory effect was sequence specific: mutant antisense hTR did not exhibit significant effects. The 2-5A itself may have exerted some effects on cell viability as an activator of RNase L, which has been shown to induce apoptosis through the decreased stability of RNA. 24 However, neither telomerase activity nor cell viability was significantly affected when cells were treated with mutant 2 -5A antisense hTR, suggesting that these chimeric oligonucleotides can work when 2-5A is linked to the specific antisense sequences. However, antisense hTR without 2-5A led to only marginal effects on telomerase activity and cell viability, indicating that antisense effect is not sufficient to achieve full inhibition of telomerase activity. Taken together, these findings suggest that the combined effect of antisense and 2 -5A actions is required for effective telomerase inhibition. Similar observations using this 2 -5A -linked anti -hTR strategy have been reported by our group and others in different types of cancers, including gliomas, 22 prostate cancer, 25 and ovarian cancer cells, 26 although these studies have not examined the telomere length before and after the treatments.
The target sequence we used was the RNA region between residues 76 and 94. Previous studies have used the template region of hTR as a target of anti -hTR because this site is required for de novo synthesis of telomeric repeats by telomerase. 8,14 -16 We tested this region, but the effects were not significant (data not shown ). It remains unclear why the region between residues 76 and 94 is specifically required for 2 -5A antisense action. One possible explanation is that the binding of 2 -5A anti -hTR onto this site may facilitate stable complex formation according to the three -dimensional structure of hTR, which may enhance 2-5A action.
Several studies have reported the effects of antisense hTR on telomere length and cell viability in a variety of cancer cells. Feng and colleagues first reported that HeLa cells transfected with antisense hTR expression vectors exhibited significant telomere shortening 1 month after the treatment, followed by apoptotic cell death at 23 -26 population doublings. 8 They speculated that the apoptotic cell death is due to the impaired telomere length, causing chromosomal instability. In contrast, our results demonstrated that the cytocidal effects of 2-5A antisense hTR emerged more rapidly in 4 to 6 days after the treatment. We compared telomere lengths in cells treated with lipofectamine alone or 2 -5A anti -hTR and found no significant difference between them in such a short period. Thus, the cytocidal effect of this agent is not merely due to the telomere impairment. The cytocidal effect was observed only in telomerase-positive cells, suggesting that this effect is mediated by telomerase inhibition. Consistent with our present results, immediate loss of cell growth by ribozyme -mediated telomerase inhibition has recently been reported by another group. 27 In this report, telomerase activity is significantly reduced and massive cell loss is induced 3 days after the transduction of ribozymes directed against hTERT. Thus, the kinetics of cell-death induction in cancer cells is not significantly dependent on telomere length and telomeres do not shorten measurably before the onset of apoptosis. Taken together, these data strongly suggest the existence of a ''fast -track'' mechanism by which diminution of telomerase can interfere with cancer cell growth and induce cell death, presumably by apoptosis. Supporting this, our data demonstrated that 2 -5A anti-hTR rapidly induces apoptosis, possibly through the activated caspase pathway. The molecular mechanism of how 2 -5A anti-hTR activates the caspace pathway remains unclear. Emerging evidence revealed that telomerase activity is associated with increased cellular resistance to apoptosis. 28 -31 Telomerase activity might therefore play some role in apoptosis -controlling mechanisms and inhibition of telomerase by 2 -5A anti -hTR may impair this pathway.
The final goal of our project is the establishment of effective gene therapy against cervical cancer. We showed that 2 -5A anti hTR is effective only in telomerase -positive cells. Fortunately, most cervical cancers are known to be telomerase positive, regardless of the histological type, whereas normal cervices are basically telomerase negative, suggesting that this agent may target only cancer tissues, minimizing the unfavorable effects on normal tissues. In addition, this cancer is visible and easily accessible under the usual gynecological examination. Antisense treatment does not usually require viral vectors for gene transfer, and the cationic liposomes used in the present study are safe and easily handled in practical Figure 7 Apoptosis inhibitors attenuate the cytocidal effects of 2 -5A antisense hTR. ME180 cells were treated with lipofectamine or wild -type 2 -5A anti -hTR in the presence of ICE inhibitors or CPP32 inhibitor. The cell viability was examined by WST -1 assays on day 4.
Cancer Gene Therapy
Telomerase inhibition by 2-5A antisense hTR N Yatabe et al medicine. A direct injection of 2-5A antisense hTR with liposomes may therefore be a potentially feasible approach as gene therapy for cervical cancer. We are currently investigating the in vivo effect of this agent in preparation for clinical trials.
